Use of osteoporosis drugs in patients with recent-onset rheumatoid arthritis in Finland

Clinical and Experimental Rheumatology

Hannu Kautiainen¹  Harri Hämäläinen¹  Timo Pohjolainen¹  Kari Puolakka¹  Salme Järvenpää¹  Lauri Virta¹ 

关键词: Osteoporosis;    rheumatoid arthritis;    drugs;    register study;    Rheumatoid arthritis;    osteoporosis;    drugs;    register study;   

DOI  :  

学科分类：医学（综合）

来源: Pacini Editore SpA

【 摘 要 】

OBJECTIVES: We investigated the implementation of pharmaceutical osteoporosis (OP) prevention in early rheumatoid arthritis (RA) in Finland. METHODS: All incident RA cases from 2000 to 2007 were identified using the national register of the Social Insurance Institution (SII) as the sole source. The use of calcium and vitamin D preparations and OP drugs during the first year was evaluated. RESULTS: A total of 14,878 incident RA patients were found. They had a mean age of 56 (SD 15) and 68% were female. Nine per cent of the total number, which equated to 11% for women and to 5% men, had purchased OP drugs. The use of OP drugs increased over time: in the 2006–2007 period, relative risk (RR) for purchase was 1.62 (95% CI 1.38–1.92) for women and 2.1 (1.34–3.30) for men compared to the 2000–2001 period. Over the 2000–2005 period, 49% of females and 52% of males used glucocorticoids (GCs) during the first year. Among the GC-users, 38% of women and 24% of men also received calcium and vitamin D preparations by prescription, and 14% of women and 6% of men also used OP drugs. For GC users, the female sex, and older age increased the risk for OP use: the respective RRs were 1.45 (95% CI 1.31–1.61), 2.54 (95% CI 2.21–2.91), and 1.060 (95% CI 1.057–1.065). CONCLUSIONS: Patients with early RA are increasingly receiving OP drugs, and the use is more frequent among patients with known risk factors.

【 授权许可】

Unknown